Clinical Trials
70 trialsNCT04481204 2026-05-04
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06732258 2026-04-29
Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
Sichuan University
Phase 1 Withdrawn
NCT02633514 2026-04-27
Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
Fudan University
Phase 3 Withdrawn
NCT01326468 2025-09-25
Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer
Thomas Jefferson University
Phase NA Withdrawn
NCT04595981 2025-04-27
Chemo-embolization for Head and Neck Cancer
University of Alabama at Birmingham
Phase 2 Withdrawn
NCT05608369 2025-04-04
HPV
Case Comprehensive Cancer Center
Phase 2 Withdrawn
NCT06017297 2024-11-12
ESR-22-21719
Georgetown University
Phase 2 Withdrawn
NCT05514912 2023-12-26
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
Emory University
Phase 2 Withdrawn
NCT05948462 2023-12-13
NSCLC
SCRI Development Innovations, LLC
Phase 2 Withdrawn
NCT04892875 2023-11-30
PANTHEoN
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT05161533 2023-10-18
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
University of Washington
Phase 2 Withdrawn
NCT01971489 2023-04-27
Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT04546828 2022-06-15
A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea
Samsung Medical Center
Phase 2 Withdrawn
NCT04625543 2022-04-26
Neoadjuvant Immunotherapy to ESCC
Qilu Hospital of Shandong University
Phase 2 Withdrawn
NCT04480190 2022-04-20
Neoadjuvant Therapy in Biliary Adenocarcinoma
University of Cincinnati
Phase 1 Withdrawn
NCT02662634 2022-03-18
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
GU Research Network, LLC
Phase 2 Withdrawn
NCT04061590 2022-03-04
Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
University of California, San Francisco
Phase 2 Withdrawn
NCT02289807 2021-10-15
Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy
Sun Yat-sen University
Phase NA Withdrawn
NCT02272699 2021-03-18
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Peking University
Phase 2/3 Withdrawn
NCT04230330 2020-11-05
Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma
National Cancer Centre, Singapore
Phase 1 Withdrawn
NCT03579758 2020-06-05
Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer
Emory University
Phase 3 Withdrawn
NCT01019278 2020-04-03
Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes
Abramson Cancer Center at Penn Medicine
Phase 2 Withdrawn
NCT03697239 2019-06-11
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
University of California, San Diego
Phase 1/2 Withdrawn
NCT03797443 2019-05-31
High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Piedmont Cancer Institute
Phase 1/2 Withdrawn
NCT03908333 2019-05-30
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Medical College of Wisconsin
Phase 1/2 Withdrawn
NCT03392571 2019-05-07
Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients
Pancreatic Cancer Research Team
Phase 2 Withdrawn
NCT03644589 2019-04-26
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer
University of Washington
Phase 2 Withdrawn
NCT00257829 2018-12-03
Improving Tumor Oxygenation in Cervical Cancer
University of California, Irvine
Phase 2 Withdrawn
NCT00006123 2018-05-16
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 1/2 Withdrawn
NCT03081039 2018-02-19
A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma
University of Louisville
Phase 3 Withdrawn
NCT02947113 2017-11-30
HYPOLAN
The Netherlands Cancer Institute
Phase 2 Withdrawn
NCT00428194 2017-11-29
Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer
Masonic Cancer Center, University of Minnesota
Phase 1 Withdrawn
NCT02944357 2017-11-17
Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
Mayo Clinic
Phase NA Withdrawn
NCT02298595 2017-11-13
Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
University of Pittsburgh
Phase 1/2 Withdrawn
NCT02382068 2017-11-09
Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin
Ohio State University Comprehensive Cancer Center
Phase NA Withdrawn
NCT02856568 2017-05-30
Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma
Mayo Clinic
Phase 1 Withdrawn
NCT01138137 2017-04-21
N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
OHSU Knight Cancer Institute
Phase 1 Withdrawn
NCT02795884 2016-12-30
Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
Yonsei University
Phase 3 Withdrawn
NCT02639767 2016-12-07
Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT00627835 2016-07-20
Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)
British Columbia Cancer Agency
Phase 1 Withdrawn
NCT01857726 2016-04-28
Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion
Seoul National University Hospital
Phase NA Withdrawn
NCT02537561 2016-02-11
Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Washington University School of Medicine
Phase 1 Withdrawn
NCT02532192 2016-01-06
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00746655 2015-12-24
SBRT + TACE for Primary Hepatocellular Carcinoma
University of Pittsburgh
Phase NA Withdrawn
NCT00003273 2015-12-03
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor
NYU Langone Health
Phase 2 Withdrawn
NCT01998347 2015-11-20
Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer
Shantou University Medical College
Phase 3 Withdrawn
NCT01928160 2015-07-13
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
Vanderbilt-Ingram Cancer Center
Phase 2 Withdrawn
NCT02120118 2015-06-09
Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors
Shin Kong Wu Ho-Su Memorial Hospital
Phase 2 Withdrawn
NCT00458315 2015-05-08
Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor
Rigshospitalet, Denmark
Phase 2 Withdrawn
NCT00881114 2015-03-27
PGx-SELECT
Georgetown University
Phase 2 Withdrawn